Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Current Leases (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Current Leases for 4 consecutive years, with $11000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Current Leases fell 97.89% to $11000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $11000.0, a 97.89% decrease, with the full-year FY2023 number at $530000.0, up 13150.0% from a year prior.
  • Current Leases was $11000.0 for Q3 2024 at Actinium Pharmaceuticals, roughly flat from $11000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $530000.0 in Q4 2023 to a low of $4000.0 in Q4 2022.
  • A 4-year average of $215666.7 and a median of $90000.0 in 2021 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: soared 13150.0% in 2023, then tumbled 97.89% in 2024.
  • Actinium Pharmaceuticals' Current Leases stood at $62000.0 in 2021, then crashed by 93.55% to $4000.0 in 2022, then skyrocketed by 13150.0% to $530000.0 in 2023, then tumbled by 97.92% to $11000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Current Leases are $11000.0 (Q3 2024), $11000.0 (Q2 2024), and $11000.0 (Q1 2024).